Starpax Biopharma Inc. files for further protection of its anticancer technology that uses magnetically steered bacteria to spread chemotherapy drugs throughout the volume of tumors. Its latest filing describes a method for preparing a subject for a medical intervention with magnetotactic bacteria tethered to treatment, imaging or diagnostic agents.
Researchers at the Spanish National Center for Cardiovascular Research (CNIC) have identified a new target that may open new avenues into pulmonary hypertension (PH) treatment. Their findings were published in Science Advances on Jan. 19, 2024.
Gradient Denervation Technologies SAS closed a €14 million (US$15 million) series A financing round that will help the company with the ongoing clinical development and evaluation of its ultrasound-based catheter device to treat pulmonary hypertension. The financing round was led by Asabys Partners, with participation from Thuja Capital and founding investor Sofinnova Partners.
Guangzhou Kaishi Pharmaceutical Co. Ltd. has patented treprostinil derivatives acting as nitric oxide (NO) donors reported to be useful for the treatment of acute respiratory distress syndrome, pulmonary arterial hypertension and arterial occlusion.
Researchers from Structure Therapeutics Inc. recently presented details on the discovery and preclinical evaluation of two new apelin receptor (APJ, APLNR) agonists – ANPA-0073 and ANPA-0137 – being developed for the treatment of pulmonary diseases.
Two research studies by Egnite Inc. presented at the American College of Cardiology Conference (ACC) could shake up the scope of how aortic stenosis (AS) is understood and treated by physicians.
Northwest Agriculture & Forestry University has disclosed short transient receptor potential channel 6 (TRPC6) antagonists reported to be useful for the treatment of cancer, sepsis, arthritis, pulmonary arterial hypertension and renal disorders.
Investigators from 35Pharma Inc. carried out in vivo testing of HS-135, an activin-receptor-based fusion protein (ActRIIB ligand trap), focusing on target engagement, effect on body composition and efficacy in pulmonary arterial hypertension (PAH).
Jiangxi Jemincare Group Co. Ltd. and Shanghai Jemincare Pharmaceuticals Co. Ltd. have divulged tricyclic hypoxia inducible factor 2-alpha (HIF-2-alpha; EPAS1) inhibitors reported to be useful for the treatment of cancer, von Hippel-Lindau disease, pulmonary hypertension and inflammatory bowel disease.
Pulmonary hypertension (PH) is characterized by persistent increases of pulmonary arterial pressure that can lead in the long term to right ventricular failure.